Prosecution Insights
Last updated: September 25, 2026
Application No. 18/705,706

DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF

Non-Final OA §102§112
Filed
Apr 29, 2024
Priority
Oct 29, 2021 — provisional 63/273,692 +1 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sensorium Therapeutics Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1439 granted / 1785 resolved
+20.6% vs TC avg
Minimal -14% lift
Without
With
+-14.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
56 currently pending
Career history
1817
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
43.5%
+3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1785 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to a preliminary amendment filed on April 29, 2024, the applicants have canceled claims 1-30 and furthermore, have added new claims 31-50. Claims 31-50 are pending in the application. Claim Rejections - 35 USC § 112 4. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 31, 43-44 and 47-50 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claim 31, variable R5c is defined but not present in the formula. In independent claim 31, variable R1c is not defined. In claim 47, variable R5c is defined but not present in the formula. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 31-33, 36 and 44-49 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by Martin (Organic Mass Spectrometry, cited on applicant’s form 1449). Martin discloses mass spectra of Sceletium alkaloids. The deuterated compounds 5,5,7,7-d mesembrine, 4,5-d mesembrine and 5,7,7-d mesembrenone (see table 2 on page 4) disclosed by Martin anticipate the instant claims when either variables R4, R3a and R3b represent D and variable m represents 2 or 1 or one of variables R4 and R5 represents D and the other represents H and variables m and n represent 2 in the instant compounds of formula (I). Allowable Subject Matter Claims 34-35 and 37-42 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 29, 2024
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §102, §112
Sep 16, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741948
BENZOTHIAZOLE AND QUINOLINE DERIVATIVES AND THEIR USE
3y 6m to grant Granted Sep 22, 2026
Patent 12740987
SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
2y 8m to grant Granted Sep 22, 2026
Patent 12735421
PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
3y 1m to grant Granted Sep 15, 2026
Patent 12735388
D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME
2y 7m to grant Granted Sep 15, 2026
Patent 12734174
TREATMENT OF A SELECTIVE POPULATION OF PATIENTS HAVING DEMENTIA WITH LEWY BODIES
1y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-14.5%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1785 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month